CRDL:NASDAQCardiol Therapeutics Inc. Analysis
Data as of 2026-09-24 - not real-time
$1.70
Latest Price
9/10Risk
Risk Level: High
Executive Summary
Cardiol Therapeutics Inc. trades at $1.70, with its short-term moving averages stacked above the longer-term ones — a bullish trend structure. The last 30 days have gained 13.3%. Momentum indicators put RSI at 40.1 (neutral) with MACD reading bearish. Price has been bracketed by support at $1.68 and resistance at $2.34.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Consensus targets land 394.1% above where the shares trade now.
On a 1-10 scale the risk profile lands at 9 — high. With 30-day volatility of 81.6%, a beta of 1.32 and a maximum drawdown of 39.1%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
Short, medium and long-term reads agree on hold, with conviction of 2/10.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Consensus targets land 394.1% above where the shares trade now.
On a 1-10 scale the risk profile lands at 9 — high. With 30-day volatility of 81.6%, a beta of 1.32 and a maximum drawdown of 39.1%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
Short, medium and long-term reads agree on hold, with conviction of 2/10.
Top Market Events
Stocks in play: Cardiol Therapeutics Inc.Here is how Cardiol Therapeutics Inc. CRDL and Charles River Laboratories CRL have performed compared to their sector...The latest company information, including net asset values, performance, holding & sectors weighting, changes in voting...
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 1/10
Key Factors
- Short-term moving averages stacked above long-term ones
- Trading above the 200-day average of 1.26
- MACD momentum is negative
Medium Term
1–3 yearsNeutral
Model confidence: 1/10
Key Factors
- Short-term moving averages stacked above long-term ones
- Trading above the 200-day average of 1.26
- Analyst targets imply +394.1% versus the current price
Long Term
> 3 yearsNeutral
Model confidence: 2/10
Key Factors
- Analyst targets imply +394.1% versus the current price
- Negative return on equity of -190.2%
- Negative free cash flow
Key Metrics & Analysis
Financial Health
P/E Ratio-7.3
ROE-190.18%
ROA-90.92%
Debt/Equity0.45
P/B Ratio11.5
Op. Cash Flow$-24047120
Free Cash Flow$-15476806
Industry P/E30.6
Technical Analysis
TrendBullish
RSI40.1
Support$1.68
Resistance$2.34
MA 20$2.00
MA 50$1.68
MA 200$1.26
MACDBearish
VolumeDecreasing
Fear & Greed Index93.36
Valuation
Target Price$8.40
Upside/Downside394.11%
GradeFair
TypeGrowth
Risk Assessment
Beta1.32
Volatility81.65%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.